Int J Clin Exp Patho
-
Int J Clin Exp Patho · Jan 2019
ReviewSerum microRNA-195 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis.
Serum microRNA-195 (miR-195) expression has been shown to be significantly up-regulated in breast cancer, which implies that it could be a useful biomarker in the early detection of breast cancer. Hence, we performed this meta-analysis to investigate the diagnostic value of miR-195 for breast cancer. Relevant articles were collected from PubMed, Scopus, Embase, the Cochrane Library, BioMed Central, ISI Web of Knowledge, China National Knowledge Infrastructure, Wan Fang Data and Technology of Chongqing databases, from inception to May 24, 2019, by two independent researchers. ⋯ The pooled results for sensitivity, specificity and DOR were 0.79 (95% CI: 0.75-0.83), 0.86 (95% CI: 0.82-0.90) and 32.05 (95% CI: 17.04-60.30), respectively; positive and negative likelihood ratios were 5.18 and 0.20, and AUC was 0.9197 (95% CI: 0.86-0.91). In addition, heterogeneity was clearly apparent but was not caused by the threshold effect. In summary, this meta-analysis revealed that miR-195 may be suitable as a potential biomarker for early diagnosis of breast cancer with high sensitivity and specificity, and further investigations are needed to demonstrate its clinical application value.
-
Int J Clin Exp Patho · Jan 2019
MicroRNA-124 represents a novel diagnostic marker in human lupus nephritis and plays an inhibitory effect on the growth and inflammation of renal mesangial cells by targeting TRAF6.
microRNAs (miRs) are short non-coding RNAs that function as guide molecules in RNA silencing by inducing mRNA degradation or blocking protein translation. Increasing evidence has shown that miRNAs play an important role in regulating the pathological process of lupus nephritis (LN), but the precise role of miR-124 in LN is still unknown. Here, we found that miR-124 expression is significantly reduced in patients with active LN compared with those patients with non-active LN and the absence of LN. ⋯ Moreover, a dual luciferase assay showed that TRAF6 was a direct target of miR-124, and the expression of TRAF6 was suppressed by miR-124 through direct binding to the 3'-UTR of mRNA. Mechanistic studies demonstrated that the over-expression of TRAF6 could abrogate miR-124-related effects on cell proliferation, apoptosis and the synthesis of inflammatory factors in HRMCs. Taken together, these findings indicate that downregulated miR-124 represents a novel diagnostic marker in human LN and plays an inhibitory effect on the growth and inflammation of renal mesangial cells by targeting TRAF6.